Rechercher des projets européens

28 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Breast CAncer STratification: understanding the determinants of risk and prognosis of molecular subtypes (B-CAST)

Date du début: 1 sept. 2015, Date de fin: 31 août 2020,

Breast tumours are heterogeneous, and result from the complex interplay of multiple lifestyle/environmental and genetic risk factors. Through the EU-funded COGS project, we have identified a large number of germline variants that influence the risk of breast cancer. In combination, these variants can identify women at wide ranges of genetic risk, even in the absence of family history of breast can ...
Voir le projet

 13

 TERMINÉ 

Imaging the Force of Cancer (FORCE)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,

Cancer is the second leading cause of mortality in EU member states with ~90% of all cancer deaths caused by metastatic spread. Despite its significance, measuring metastatic potential as well as potential indicators of therapy efficacy remain unmet clinical challenges. Recently, it has been demonstrated in vitro, that aggressive metastatic cells pull on their surroundings suggesting that metastat ...
Voir le projet

 18

 TERMINÉ 

The use of genetic profiling to guide prostate cancer targeted screening and cancer care (BARCODE)

Date du début: 1 oct. 2014, Date de fin: 30 sept. 2019,

... and reduce costs. The PI will spend 35% of her time on this project and she will not charge for her time spent on this grant as she is funded by The University of London UK. The research team at The Institute Of Cancer Research, London, UK is a multidisciplinary team which leads the field of genetic predisposition to prostate cancer and its clinical application and so is well placed to deliver on ...
Voir le projet

 1

 TERMINÉ 

QUantitative Imaging in Cancer: CONnecting CEllular Processes with Therapy (QUIC-CONCEPT)

Date du début: 1 sept. 2011, Date de fin: 31 déc. 2017,

The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials. Our vision for January 2016 is that drug developers can incorporate these IBs for decision- ...
Voir le projet

 26

 TERMINÉ 

Structural basis of Cullin-RING ligase regulation by the COP9 signalosome (EMCOP9CRL)

Date du début: 12 oct. 2015, Date de fin: 11 oct. 2017,

The components of the Cullin-RING Ligase (CRLs) E3 ubiquitin ligase family play key roles in a wide range of cellular processes including stress response, signal transduction, apoptosis and cell cycle progression, and accordingly, defects in their function and/or regulation are prominent in many pathologies including cancer. The modular CRL architecture is centred upon one of seven different culli ...
Voir le projet

 1

 TERMINÉ 

Transcribed-Ultraconserved Regions as novel biomarkers and therapeutic targets in liver cancer (LIVERNCODE)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

Hepatocellular carcinoma (HCC) is the sixth most common malignancy in the world. In Scotland incidence of liver cancer has increased of 60% in men from 2000 to 2010. The outcome of patients with advanced HCC remains poor. Thus, novel therapeutic approaches based on targeting oncogenic driver pathways in HCC are urgently needed, as well as informative prognostic markers that guide the use of existi ...
Voir le projet

 2

 TERMINÉ 

Targeting microRNAs for ColoRectal Cancer Therapy (TAMIRCRT)

Date du début: 1 juin 2013, Date de fin: 31 mai 2017,

MicroRNAs are small non-coding RNAs involved in cell homeostasis and carcinogenesis. MicroRNA deregulation is associated with colorectal cancer (CRC) progression. My study proposes to identify genetic and epigenetic events leading to microRNAs deregulation and use them as targets for drug development. My research proposal will address two important questions. First it will assess the contribution ...
Voir le projet

 2

 TERMINÉ 

RNA Polymerase III Rpc4/Rpc5 subcomplex and Selenocysteine tRNA transcription (Human Rpc5)

Date du début: 1 mai 2015, Date de fin: 30 avr. 2017,

In higher eukaryotes, the RNA polymerase III (Pol III) participates in the transcription of small RNAs such as the tRNAs. RNA polymerase recruitment to their specific promoter relies on the activity of several transcription factors. Brf2 is a transcription factor that exclusively recruits RNA Pol III at the selenocysteine tRNA (tRNASec). Unpublished work from our group has unravelled an unanticipa ...
Voir le projet

 1

 TERMINÉ 

Decision-making within cells and differentiation entity therapies (DECIDE)

Date du début: 1 mars 2013, Date de fin: 28 févr. 2017,

...h organisations. ESRs will also receive management training. This research and training, which will develop our ESRs as versatile scientists, will involve the combined efforts of prestigious research institutes and universities, Poland’s leading governmental pharmaceutical R & D institute, two successful biopharmaceutical companies and a leading management consultancy."
Voir le projet

 8

 TERMINÉ 

A European Platform for Translational Cancer Research (EUROCANPLATFORM)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,

Europe has a number of advantages as regards developing translational cancer research, yet there is no clear European strategy to meet the increasing burden posed by cancer. The FP6 Eurocan+Plus project analysed the barriers underlying the increasing fragmentation of cancer research and stressed the need to improve collaboration between basic/preclinical and comprehensive cancer centres (CCCs), in ...
Voir le projet

 29

 TERMINÉ 

Circulating Tumor Cells TheRapeutic APheresis: a novel biotechnology enabling personalized therapy for all cancer patients (CTCtrap)

Date du début: 1 sept. 2012, Date de fin: 31 août 2016,

"Chemotherapy is slowly being supplemented by a new generation of drugs that recognize specific targets in or on cancer cells and has proven to be more effective with markedly fewer side effects. During the course of the disease alternative oncogenic signaling pathways take over inevitably leading to drug resistance. As a consequence renewed tumor analysis is required to redefine the optimal treat ...
Voir le projet

 12

 TERMINÉ 

Studying Resistance to Cancer Therapeutics in Prostate Cancer (RESICT-PC)

Date du début: 1 mai 2014, Date de fin: 30 avr. 2016,

... data of fresh-frozen CRPC biopsies collected prior to, and after progression on abiraterone and/or enzalutamide treatment and patient-matched archival hormone therapy-naïve samples collected at The Institute of Cancer Research, will be analyzed together with the computational oncology group at University of Trento (PI: Dr Demichelis). Second, single CTC isolation will be performed using a researc ...
Voir le projet

 1

 TERMINÉ 

CHD1 Deletion: Implications to Outcome and Treatment in Prostate Cancer (CDELP)

Date du début: 4 avr. 2014, Date de fin: 3 avr. 2016,

Prostate cancer can be stratified as ETS gene rearranged (ETSR) andnon-rearranged (ETSNR), with the latter comprising a heterogeneousgroup of 50-60% of all cancers. This project will characterize a subgroupof ETSNR cancers that have a CHD1 deletion (CHD1del). Recentsequencing studies have elucidated CHD1- cancers as ETSNR, andcommonly PTEN and p53 wildtype and SPOP mutated, comprising up to26% of ...
Voir le projet

 1

 TERMINÉ 

Systems Biology of Colorectal Cancer (SYSCOL)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,

Colorectal cancer (CRC) is one of the most common cancers in both males and females, and it is perhaps the best understood of all epithelial tumors in terms of its molecular origin. Yet, despite large amount of work that has concentrated on understanding of colon tumorigenesis, we still do not know the full complement of molecular lesions that are individually necessary – and together sufficient – ...
Voir le projet

 11

 TERMINÉ 

The DNA damage response and breast cancer (DDRESPONSE)

Date du début: 1 févr. 2011, Date de fin: 31 janv. 2015,

We will exploit the DNA damage response (DDR) to assess and predict individual susceptibility and response focussed on breast cancer and breast cancer therapies. The 1st targeted therapy based on the DDR is inhibition of PARP by olaparib, which induces synthetic lethality in cancer cells with a specific DDR defect. Our members discovered olaparib, which is currently in Phase II trials. Its use in ...
Voir le projet

 6

 TERMINÉ 

Breast Cancer Somatic Genetics Study (BASIS)

Date du début: 1 juil. 2010, Date de fin: 31 déc. 2014,

"All cancers arise due to somatically acquired mutations in their genomes which alter the function of key cancer genes. Understanding these critical mutational events underlying cancer development is paramount for advancing prevention, early detection, monitoring and treatment of the disease. Breast cancer is the most common class of cancer diagnosed in women worldwide with more than one million c ...
Voir le projet

 16

 TERMINÉ 

Sequence of Mutational Events and Sub-clonal Architecture in Plasma Cell Myeloma (ICRMYELOMA)

Date du début: 1 août 2012, Date de fin: 31 juil. 2014,

"Plasma cell myeloma (PCM) is an incurable malignancy. Cytogenetics, molecular genetics and single nucleotide polymorphism arrays have shown significant genetic complexity in PCM. However, these screens reflect only the predominant clonal population and genetic-based prognostic classification of PCM can predict the outcome only in a subset of cases. To better understand the oncogenesis of PCM comb ...
Voir le projet

 1

 TERMINÉ 

Pharmaceutical Medicine Training Programme (PHARMATRAIN)

Date du début: 1 mai 2009, Date de fin: 30 avr. 2014,

"The proposed Pharmaceutical Medicine Training Programme provides a comprehensive solution for the complex needs of integrated drug development for all professionals involved, incl. physicians, pharmaceutical scientists,biologists, biometricians, health economists, and safety and regulatory scientists from universities, regulatory agencies, large, middle-sized and small pharmaceutical enterprises, ...
Voir le projet

 52

 TERMINÉ 

Collaborative Oncological Gene-environment Study (COGS)

Date du début: 1 mai 2009, Date de fin: 31 janv. 2014,

... consortia have collaborated successfully over the past years and results have been presented in world leading scientific journals such as Nature, Nature Genetics and Journal of the National Cancer Institute. These papers reflect that collaboration has been ongoing and that is has so far been very successful. We will also build on an existing European Commission project, TRANSBIG, thus adding val ...
Voir le projet

 16

 TERMINÉ 

European Paediatric Oncology Off-Patent Medicines Consortium (EPOC)

Date du début: 1 févr. 2009, Date de fin: 31 oct. 2013,

Cancer chemotherapy has a key role in the successful treatment of a number of childhood cancers. Nevertheless, at least 20% of patients are not cured by current therapies and a significant number experience debilitating toxicities. Given the high cure rates and potential life-span of survivors of childhood cancer, it is particularly important to minimize the impact of potential chronic toxicities. ...
Voir le projet

 11

 TERMINÉ 

pARylation-mediated regulation of cancer pathways (pARylome)

Date du début: 1 mars 2011, Date de fin: 8 août 2013,

Poly(ADP)ribosylation (pARylation) is an important post-translational modification of proteins that affects diverse biological processes such as DNA damage repair, apoptosis and transcription. The conjugation of Poly(ADP)-ribose (pADPr) to target proteins is mediated by members of the Poly(ADP)-ribose polymerase (ARTD/PARP) protein family. ADPr can be attached either as a single moiety or as chain ...
Voir le projet

 1

 TERMINÉ 

Molecular mechanisms of melanoma invasion (Melanoma Invasion)

Date du début: 1 juin 2011, Date de fin: 14 juin 2013,

Malignant melanoma is highly invasive and metastatic resulting in a major clinical problem in management of the disease. The aim of this project is to gain a better understanding of mechanisms of cell migration to identify novel therapeutic targets to block invasion. Disruption of cell signalling pathways that dynamically regulate the cytoskeleton underlie the altered migratory potential of tumour ...
Voir le projet

 1

 TERMINÉ 

"ECNIS2: towards ECNIS Centre for Research and Education on Cancer, Environment and Food" (ECNIS2)

Date du début: 1 juin 2011, Date de fin: 31 mai 2013,

"The proposed project ECNIS2 aims at continuing the integrative and coordinative works initiated during ECNIS network with an ultimate goal of transforming network into a virtual centre, the European Centre for Research and Education on Cancer, Environment and Food (ECRECEF).ECNIS has already laid foundations for the development of the centre by bringing together researchers from different discipl ...
Voir le projet

 23

 TERMINÉ 

Safety and Appropriateness of Growth hormone treatments in Europe (SAGhE)

Date du début: 1 juin 2009, Date de fin: 30 nov. 2012,

Recombinant growth hormone (GH) has been used since 1985. Current indications for GH use in children include GH deficiency and an increasing number of conditions where childhood short stature is not primarily due to deficient GH secretion. Approximately 40 000 children in the EU are treated with daily injections of GH. The efficacy of GH to increase adult height is undisputed in children with seve ...
Voir le projet

 10

 TERMINÉ 

The influence of Her2 status on mammary stem/progenitor cells (HER2 MAMMARYSTEMCELL)

Date du début: 1 oct. 2009, Date de fin: 30 sept. 2011,

"c-ERBB2/HER2 is a gene that is found overexpressed in ~25% of mammary tumours, and defines the molecular signature of one of the breast cancer subtypes: the HER2-positive tumour subtype. However, the role of the c-ErbB2 tyrosine kinase and the stem cell of origin of HER2-positive breast cancers are poorly understood. Our project aims to study the relationship between c-ErbB2 function and normal a ...
Voir le projet

 1

 TERMINÉ 

Oral Off-patent Oncology Drugs for Kids (03K)

Date du début: 1 sept. 2008, Date de fin: 31 août 2011,

"There is an urgent need for appropriate oral formulations of anticancer drugs for the treatment of paediatric malignancies in children. The goal of the O3K consortium is to develop oral liquid formulations of Cyclophosphamide and Temozolomide, important chemotherapeutics which have been identified in the list of paediatric needs by EMEA (EMEA/197972/2007). Both off-patent drugs are widely used or ...
Voir le projet

 9

 TERMINÉ 

Synthetic lethality approaches to BRCA-associated cancer (SYNTHLE BRCA)

Date du début: 1 sept. 2008, Date de fin: 31 août 2010,

"Mutations in BRCA1 and BRCA2 genes confer high lifetime risks of developing breast and other cancers. Moreover, several studies suggest that tumours arising in mutation carriers have generally lost the wild-type allele and do not express functional BRCA1 or BRCA2 proteins. Both BRCA proteins are important for repair of double strand DNA breaks by homologous recombination. The subject of this proj ...
Voir le projet

 1

 TERMINÉ 

Characterization of myoepithelial differentiation in basal-like breast cancer cells (Basal Breast Cancer)

Date du début: 1 juin 2008, Date de fin: 31 mai 2010,

Translational research in cancer is one of the thematic priorities within FP7 Health Investigation Programme. Breast cancer is the most frequent tumour type in European women. 20-25% of breast carcinomas express myoepithelial markers, thus showing the basal-like phenotype. Basal-like tumours are typically high-grade, aggressive cancers with poor prognosis. Since basal-like phenotype closely resemb ...
Voir le projet

 1